ReviewJournal of clinical medicine2023
Levodopa-Induced Dyskinesias in Parkinson's Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 6 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Effects of transcutaneous auricular vagus nerve stimulation on motor and gait performance in Parkinson's disease: a meta-analysis of randomized controlled trials.Journal of neurology · 2026Pooled it
- AI Video Analysis in Parkinson's Disease: A Systematic Review of the Most Accurate Computer Vision Tools for Diagnosis, Symptom Monitoring, and Therapy Management.Sensors (Basel, Switzerland) · 2025Pooled it
- Computer Vision Technologies in Movement Disorders: A Systematic Review.Movement disorders clinical practice · 2025Pooled it
- Evaluation of the efficacy and cost-effectiveness of safinamide versus rasagiline: a systematic review.Journal of comparative effectiveness research · 2025Pooled it
- Antidiabetic drugs in Parkinson's disease: a comprehensive meta-analysis on efficacy and safety with trial sequential analysis and GRADE evaluation.Inflammopharmacology · 2025Pooled it
- Machine learning and wearable sensors for automated Parkinson's disease diagnosis aid: a systematic review.Journal of neurology · 2024Pooled it
- The Hidden Burden of Parkinson's Disease in Cambodia: A Call to Action.Public health challenges · 2026Article
- Flexible and Self-Powered Wearable Sensors for Tremor Monitoring in Parkinson'S Disease: Recent Advances in Materials and Device Architectures.Advanced healthcare materials · 2026Review
- Natural Frequencies of Levodopa-Induced Dyskinesia in Parkinson's Disease.Annals of clinical and translational neurology · 2026Article
- Population pharmacokinetic analyses comparing immediate-release levodopa/carbidopa, controlled-release levodopa/carbidopa, and IPX203. Findings from a phase 1 study in healthy volunteers.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Neuroprotective Effects of Lycopene in Parkinson's Disease Mice: Potential Modulation of DAT/SLC6A3-Mediated Dopaminergic Pathway.Nutrients · 2026Article
- Noninvasive Brain Stimulation for Parkinson's Disease: Therapeutic Applications and Clinical Perspectives.Journal of movement disorders · 2026Article
- Levodopa-Induced dyskinesia in Latin America: Prevalence and associated clinical factors in the LARGE-PD cohort.Journal of Parkinson's disease · 2026Article
- Investigation of the Effects of Saffron on Neuroprotection and Circadian Rhythm in anPharmaceuticals (Basel, Switzerland) · 2026Article
- Serum ferritin, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio are associated with levodopa-induced dyskinesia severity in Parkinson's disease.BMC neurology · 2026Article
- Levodopa-Carbidopa Intestinal Gel Improves Dyskinesia in Parkinson's Disease: Post Hoc Analysis from the COSMOS Study.Movement disorders clinical practice · 2026Observational
- AI-Driven Analysis of Wrist-Worn Sensor Data for Monitoring Individual Treatment Response and Optimizing Levodopa Dosing in Parkinson's Disease.Sensors (Basel, Switzerland) · 2025Article
- Parkinson's disease: genetics and neuroinflammatory insights.Inflammopharmacology · 2025Review
- Levodopa treatment: impacts and mechanisms throughout Parkinson's disease progression.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Levodopa-induced dyskinesia in Parkinson's disease: an updated review of pharmacological treatments.Frontiers in aging neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since its first introduction, levodopa has become the cornerstone for the treatment of Parkinson's disease and remains the leading therapeutic choice for motor control therapy so far. Unfortunately, the subsequent appearance of abnormal involuntary movements, known as dyskinesias, is a frequent drawback. Despite the deep knowledge of this complication, in terms of clinical phenomenology and the temporal relationship during a levodopa regimen, less is clear about the pathophysiological mechanisms underpinning it. As the disease progresses, specific oscillatory activities of both motor cortical and basal ganglia neurons and variation in levodopa metabolism, in terms of the dopamine receptor stimulation pattern and turnover rate, underlie dyskinesia onset. This review aims to provide a global overview on levodopa-induced dyskinesias, focusing on pathophysiology, clinical manifestations, therapy management strategies and future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.